Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...
A joint framework is being built to convert Israeli academic target biology into viable small-molecule programs by integrating AI-enabled design with rigorous experimental validation. ChemPass AI™ ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...
Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...
Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results